WEIWEN YING, Ph.D.

Founder & Chief Executive Officer

Dr. Ying is the inventor of Ranok’s innovative targeted protein degradation technology. He was most recently Co-founder and President of the immuno-oncology startup Capten Therapeutics and brings to Ranok over 19 years’ industry experience in medicinal chemistry, drug discovery, preclinical and clinical development. Previously, he was Vice President of Discovery Chemistry at Synta Pharmaceuticals and was responsible for creating a program in protein homeostasis that resulted in advancing the HSP90 inhibitor ganetespib from discovery to Phase 3. He also conceived Synta’s novel tumor-targeted drug conjugate technology, which was out-licensed to Tarveda Therapeutics for up to $249M USD. Dr. Ying was a post-doctoral fellow in Biophysics at Yale University and State University of New York at Stony Brook and received his Ph.D. and MS degrees in Organic Chemistry at Clemson University and Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences.

Junlin Wang

Chairman & CEO, Shanghai UNIONLAB

Mr. Wang is a co-founder of Ranok Therapeutics and also Chairman and CEO of Shanghai UNIONLAB Co. Ltd., a rapidly growing oncology-focused clinical CRO in China. Prior to this, he was President and CEO of Shanghai CP Guojian Pharmaceutical Company. Under his leadership, CP Guojian grew to be one of China’s leading developers of biosimilars, with multiple marketed drugs. Previously, he was Deputy General Manager of Lansheng Guojian Pharmaceutical Company and a Manager at Lansheng CNSK Venture Capital. Mr. Wang is a graduate of Fudan University and received his M.Sc. degree in Professional Accounting from Chinese University of Hong Kong.